Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations

Background: Increased expression of type I interferon (IFN)-regulated genes has been described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) and other rheumatic disorders. Only isolated studies have examined the type I IFN gene expression in antiphosholipid syndrome...

Full description

Bibliographic Details
Main Authors: Eleni Palli, Evrydiki Kravvariti, Maria G. Tektonidou
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-03-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.00487/full
id doaj-c4b0bf4c9ddd48a7951767b4e6cac079
record_format Article
spelling doaj-c4b0bf4c9ddd48a7951767b4e6cac0792020-11-24T21:16:17ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-03-011010.3389/fimmu.2019.00487430220Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory AssociationsEleni PalliEvrydiki KravvaritiMaria G. TektonidouBackground: Increased expression of type I interferon (IFN)-regulated genes has been described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) and other rheumatic disorders. Only isolated studies have examined the type I IFN gene expression in antiphosholipid syndrome (APS), while efforts to evaluate associations with APS-related factors are scarce.Objective: Our aim was to investigate the type I IFN signature in patients with primary APS (PAPS), SLE/APS, and SLE in comparison with healthy controls, and to evaluate associations with disease-related characteristics.Methods: We measured the type I IFN score, derived from relative expressions of three IFN-inducible genes (MX-1, IFIT-1, and IFI-44) in peripheral blood mononuclear cells from 55 patients with PAPS, 34 with SLE/APS, 48 with SLE, and 28 controls. In patients with PAPS, we performed multivariate regression to examine associations of type I IFN score with their clinical, laboratory and treatment characteristics.Results: Type I IFN score was increased in all patient groups vs. controls (p = 0.028, p = 0.027, p = 0.028 for PAPS, SLE/APS, and SLE, respectively). IFI-44 had the most pronounced expression. In patients with PAPS, multivariate linear regression revealed positive associations of type I IFN score with female gender (b-coefficient = 0.49; 95% CI 0.04, 0.94; p = 0.034) and IgG or IgM anti-β2GPI antibodies (b-coefficient = 0.53; 95% CI 0.10, 0.96; p = 0.017), and negative associations with age (b-coefficient = −0.02/year; 95% CI −0.04, −0.01; p = 0.027) and hydroxychloroquine use (b-coefficient = −0.51; 95% CI-0.96, −0.06; p = 0.027).Conclusion: Type I IFN score is increased in PAPS and correlated positively with anti-β2GPI antibodies and negatively with hydroxychloroquine use.https://www.frontiersin.org/article/10.3389/fimmu.2019.00487/fullantiphospholipid syndromesystemic lupus erythematosustype I Interferon signaturetype I Interferon scoreantiphospholipid antibodiesanti-b2-glycoprotein I antibodies
collection DOAJ
language English
format Article
sources DOAJ
author Eleni Palli
Evrydiki Kravvariti
Maria G. Tektonidou
spellingShingle Eleni Palli
Evrydiki Kravvariti
Maria G. Tektonidou
Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
Frontiers in Immunology
antiphospholipid syndrome
systemic lupus erythematosus
type I Interferon signature
type I Interferon score
antiphospholipid antibodies
anti-b2-glycoprotein I antibodies
author_facet Eleni Palli
Evrydiki Kravvariti
Maria G. Tektonidou
author_sort Eleni Palli
title Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
title_short Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
title_full Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
title_fullStr Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
title_full_unstemmed Type I Interferon Signature in Primary Antiphospholipid Syndrome: Clinical and Laboratory Associations
title_sort type i interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2019-03-01
description Background: Increased expression of type I interferon (IFN)-regulated genes has been described in blood and tissue cells from patients with systemic lupus erythematosus (SLE) and other rheumatic disorders. Only isolated studies have examined the type I IFN gene expression in antiphosholipid syndrome (APS), while efforts to evaluate associations with APS-related factors are scarce.Objective: Our aim was to investigate the type I IFN signature in patients with primary APS (PAPS), SLE/APS, and SLE in comparison with healthy controls, and to evaluate associations with disease-related characteristics.Methods: We measured the type I IFN score, derived from relative expressions of three IFN-inducible genes (MX-1, IFIT-1, and IFI-44) in peripheral blood mononuclear cells from 55 patients with PAPS, 34 with SLE/APS, 48 with SLE, and 28 controls. In patients with PAPS, we performed multivariate regression to examine associations of type I IFN score with their clinical, laboratory and treatment characteristics.Results: Type I IFN score was increased in all patient groups vs. controls (p = 0.028, p = 0.027, p = 0.028 for PAPS, SLE/APS, and SLE, respectively). IFI-44 had the most pronounced expression. In patients with PAPS, multivariate linear regression revealed positive associations of type I IFN score with female gender (b-coefficient = 0.49; 95% CI 0.04, 0.94; p = 0.034) and IgG or IgM anti-β2GPI antibodies (b-coefficient = 0.53; 95% CI 0.10, 0.96; p = 0.017), and negative associations with age (b-coefficient = −0.02/year; 95% CI −0.04, −0.01; p = 0.027) and hydroxychloroquine use (b-coefficient = −0.51; 95% CI-0.96, −0.06; p = 0.027).Conclusion: Type I IFN score is increased in PAPS and correlated positively with anti-β2GPI antibodies and negatively with hydroxychloroquine use.
topic antiphospholipid syndrome
systemic lupus erythematosus
type I Interferon signature
type I Interferon score
antiphospholipid antibodies
anti-b2-glycoprotein I antibodies
url https://www.frontiersin.org/article/10.3389/fimmu.2019.00487/full
work_keys_str_mv AT elenipalli typeiinterferonsignatureinprimaryantiphospholipidsyndromeclinicalandlaboratoryassociations
AT evrydikikravvariti typeiinterferonsignatureinprimaryantiphospholipidsyndromeclinicalandlaboratoryassociations
AT mariagtektonidou typeiinterferonsignatureinprimaryantiphospholipidsyndromeclinicalandlaboratoryassociations
_version_ 1726016293770887168